CASI Pharmaceuticals IncNASDAQ:CASI
- LAST PRICE5.3000
- TODAY'S CHANGE (%)0.0500 (0.9524%)
- Bid / Lots5.1000/ 10
- Ask / Lots5.5000/ 3
- Open / Previous Close5.1600 / 5.2500
- Day Range
- 52 Week Range
- Volume7,820
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CASI |
|---|---|---|
| 09:32 ET | 367 | 5.31 |
| 09:50 ET | 171 | 5.2 |
| 10:08 ET | 100 | 5 |
| 10:11 ET | 100 | 5.02 |
| 10:38 ET | 100 | 5.14 |
| 10:40 ET | 1300 | 5.254347 |
| 10:42 ET | 500 | 5.3 |
Nov 15, 2024
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results, from 8:02AM ET on Friday Nov 15, 2024 by Dow Jones
8:02AM ET on Friday Nov 15, 2024 by Dow Jones
Oct 24, 2024
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia, from 8:02AM ET on Thursday Oct 24, 2024 by Dow Jones
8:02AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CASI Pharmaceuticals Inc | 70.4M | -2.4x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.2M | -0.5x | --- |
Marinus Pharmaceuticals Inc | 17.8M | -0.1x | --- |
BGM Group Ltd | 50.6M | -6.3x | --- |
Bon Natural Life Ltd | 6.3M | 0.6x | +78.05% |
Company Information
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Contact Information
- Headquarters
- 1701-1702, China Central Office Tower 1,BEIJING, BEJ, China 100025
- Phone
- 106-561-8789
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Wei-Wu He
- President, Principal Financial Officer
- Wei Zhang
- Chief Operating Officer
- Chunhua Wang
- Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China
- Huang Hai
- Executive Vice President, Chief Medical Officer
- Alexander Zukiwski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.4M |
|---|---|
Revenue (TTM) | $22.1M |
Shares Outstanding | 13.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-2.23 |
Book Value | $1.81 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -145.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
